Merck reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda but total revenue fell in the quarter from disruptions due to the NotPetya cyber attack and loss of market share for many of its older drugs.

Sales of Keytruda more than doubled to $ 1.05 billion in the third quarter but were not enough to boost Merck’s total revenue, which fell about 2 percent to $ 10.33 billio…
Health Care